Drug Trial Radar · NCT06249919
A Phase 1b/2a, Study Evaluating the Safety, PK/PD and Efficacy of NS101 in Healthy Volunteers and SSNHL Patients
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Feb 15, 2024
Primary completion
May 4, 2026
Study completion May 4, 2026
Sponsor
- Lead sponsor
- Neuracle Science Co., LTD.Industry
- Sponsor type
- Industry
- Collaborators
- Samsung Medical Center; Severance Hospital; Korea University Anam Hospital
- First posted
- Feb 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this 2 step-up, exploratory study is to test safey, tolerability and PK/PD profiles in healthy volunteers and safety, tolerability and efficacy in sudden sensorineural hearing loss patients as an early salvage therapy. The main questions it aims to answer are: 1. whether is it safe and tolerable when healthy volunteers and sudden sensorineural hearing loss patients take multiple doses of NS101 against FAM19A5 2. whether is it effective in reversing hearing capability in sudden sensorineural hearing loss patients who fails to show sufficient recovery despite of oral standard steroid therapy. Patients and heathly volunteers will be given NS101 15mg/kg or 30mg/kg systemically less than 3 months per protocol. This is placebo controlled, double blinded study, which means there will be a group who receives placebo (i.e. fake drug) for study purpose.
Conditions
- Seneorineural Deafness
- Sudden Sensorineural Hearing Loss
Interventions
NS101Biological
NS101 is anti FAM19A5 antibody expected to play as a synapse organizer and reversing synapse dysfunction in various neurological diseases
PlaceboBiological
Placebo (i.e. fake drug without active pharmaceutical ingredient) of NS101
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b part: Change from Baseline in Safety ProfilesTime frame: Baseline, Day1, Day2, Day3, Day14, Day15, Day16, Day17, Day28, Day29, Day30, Day32, Day43
- Phase 2a part: Changes from Baseline in Safety ProfilesTime frame: Baseline, Week1, Week2, Week4, Week6, Week8, Week10, Week12, Week16, Week20
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
SCH University Hospital Bucheon
Bucheon-si, South Korea
Samsung Changwon Hospital
Changwon, South Korea
Keimyung University Dongsan Hospital
Daegu, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Inje University Ilsan Paik Hospital
Ilsan, South Korea
Pusan National University Hospital
Pusan, South Korea
Hallym University Sacred Heart Hospital
Pyeongchon, South Korea
Asan Medical Center
Seoul, South Korea
Catholic University Seoul St. Mary's Hospital
Seoul, South Korea
Ewha Women's University Mokdong Medical Center
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Yonsei University Severance Hospital
Seoul, South Korea
Wonju Severance Christian Hospital
Wŏnju, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.